Prevalences, nuances of presentation, and likely clinical course of myocarditis after use of some vaccines against SARS-CoV-2 are in sharper view after additions to the literature this week.
A third, booster dose of either the ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), AD26.COV2-S (Janssen) or CoronaVac (SinoVac) coronavirus vaccine induce a significant increase in antibody levels in those who have previously received two doses of CoronaVac.